Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Johansen, Helle Krogh ^a   Gøtzsche, Peter C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; PSEUDOMONAS VACCINE;

AGE; BODY HEIGHT; BODY MASS; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOGENICITY; LUNG FIBROSIS; LUNG INFECTION; LUNG LAVAGE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; REVIEW; SEX; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; COMPLICATION; CYSTIC FIBROSIS; IMMUNOLOGY; META ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891705714     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001399.pub3     Document Type: Review

References (33)

1. Döring G. Relevant issues in bacterial vaccine development for patients with cystic fibrosis [abstract]. Pedaitric Pulmonology 2003;Suppl 25:128-9.
2. Döring G, Dorner F. A multicenter trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Institute Mitteilungen 1997;98:338-44.
3. Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proceedings of the National Academy of Science USA 2007;104:11020-5.
4. Clinical trial protocol, No. KV 9909. Double-blind, randomised, placebo-controlled, multi-centre trial to determine the efficacy of Aerugen Berna Vaccine to prevent respiratory tract infections with P. aeruginosa in non-colonised patients with cystic fibrosis. Medical Department, Swiss Serum and Vaccine Institute, Bern 2000 (May).
5. Press release. Crucell announces suspension of Aerugen(R) clinical development. http://cws.huginonline.com/C/132631/PR/200607/1064252_5.html (accessed 19 Dec 2007).
6. Hiller EJ. Was Pseudomonas vaccine really harmful [abstract]?. Proceedings of the 18th European Cystic Fibrosis Conference; 1993 May; Madrid. 1993:113.
7. Hiller EJ, Langford DT. Pseudomonas vaccine: a prospective study [abstract]. Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney. 1988:13.
8. Hiller EJ, Langford DT. Vaccination of non-colonised CF patients against Pseudomonas - a prospective study. 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 Nov; Jerusalem. 1985:33.
9. Langford DT, Hiller EJ. A prospective, controlled study of polyvalent pseudomonas vaccine in patients with cystic fibrosis [abstract]. Proceedings of the 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 Oct; Athens. 1983:60-7.
10. Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - three year results. Archives of Disease in Childhood 1984;59(12):1131-4.
11. Day AJ, Weller PH, Jones RJ, Roe EA. Immunological responses following vaccination with pseudomonal aeruginosa vaccine [abstract]. Proceedings of the 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton. 1984:270.
12. Gibbs GE. Early trials of Pseudomonas vaccine in Cystic Fibrosis [abstract]. Proceedings of the 11th Annual Meeting Cystic Fibrosis Club; 1970 April 29; Atlantic City. 1970:14.
13. Cryz SJ, Lang A, Rudeberg A, Wedgewood J, Que JU, Furer E, et al.Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-Polysaccharide-Toxin A conjugate vaccine. Behring Institute Mitteilungen 1997;98:345-9.
14. Lang AB, Rudeberg A, Que JU, Wedgewood J, Furer E, Schaad UB, et al.Longterm protection against Pseudomonas aeruginosa (PA) infections in patients with cystic fibrosis (CF): results of a 9-year vaccine study [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):s49.
15. Lang AB, Rudeberg A, Wedgewood J, Que JU, Furer E, Schaad UB. Ten years experience with a new O-polysaccharide conjugate vaccine in patients with cystic fibrosis [abstract]. Proceedings of the XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:170.
16. Lang AB, Ruedeberg A, Schöni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatric Infectious Disease Journal 2004;23(6):504-10.
17. Schaad UB, Lang AB, Wedgewood J, Rudeberg A, Que JU, Furer E, et al.Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991;338(8777):1236-7.
18. Döring G, Bellon G, Knight R. Immunology of cystic fibrosis. Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
19. Döring G, Conway SP, Heijerman HGM, Hodson M, Høiby N, Smyth A, Touw DJ for the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
20. Döring G, Høiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2004;3(2):67-91.
21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
22. Hiller EJ. Personal communication 21 Oct 2005.
23. Høiby N. Microbiology of cystic fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
24. Høiby N. Prospective for the prevention and control of Pseudomonas infection in children with cystic fibrosis. Pediatric Drugs 2000;2(6):451-63.
25. Johansen HK, Hougen HR, Cryz SJ Jr, Rygaard J, Høiby N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. American Journal of Respiratory and Critical Care Medicine 1995;152(4 Pt 1):1337-46.
26. Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes D editor(s). Cystic Fibrosis. London: Chapman and Hall, 1995:1-13.
27. Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Høiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Acta Pathologica, Microbiologica et Immunologica Scandinavia 2000;108(5):329-35.
28. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, et al.Reduced IL-10 secretion by CD4+T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology 1996;106(2):374-88.
29. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
30. Sheppard MN. The Pathology of Cystic Fibrosis. In: Hodson ME, Geddes DM editor(s). Cystic Fibrosis. London: Chapman & Hall Medical, 1995.
31. Wheeler WB, Williams RN, Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. Journal of Pediatrics 1984;104(5):695-9.
32. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001399.pub2]
33. Keogan MT, Johansen HK. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001399]